Kornimate/medical-research-clean huggingface dataset:
validation of clinical efficacy and development of new diagnostic algorithm of probe-based confocal laser endomicroscopy in patients with lower gastrointestinal disorder

Conditions: Lower Gastrointestinal Disorders

Summary: the aims of this research are to validate and develop of therapeutic strategies for patients with colorectal lesions in real time through pcle(probe-based confocal laser endomicroscopy). endomicroscopy is a technique for obtaining histology-like images from inside the human body in real-time. total objections are 311 patients. specific research topics are as below. 1. diagnosis and classification of colon polyps through pcle 2. evaluation of the depth of invasion of colorectal cancer or lateral growth type tumor through the pcle 3. differential diagnosis of colorectal submucosal tumor through the pcle 4. differential diagnosis of ileocecal ulcers through the pcle the study will be conducted to measure sensitivity, specificity, accuracy, amphoteric predict of pcle diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and will develope a new classification method based on this.


Eligibility criteria:
inclusion criteria: * adults over 20 years old * patients with colorectal polyps * patients who undergo endoscopic submucosal dissection (esd) due to lateral spreading tumors or early colorectal cancer * patients with submucosal tumor in colorectal cancer * patients with ileocecal ulcers * patients who consented to research exclusion criteria: * patients who are impossible to biopsy or polypectomy due to underlying diseases. * patients who are not able to end the esd because of a complication * patients who are already known the cause of ileocecal ulcers before the pcle. * patients with contraindications to the use of disease fluorescent contrast agents * patients who did not consent to research * patients who are unsuitable for clinical trials in charge of the attending physician.

Keywords: probe-based confocal laser endomicroscopy, lower gastrointestinal disorders
age-related changes of crystalline lens tilt and decentration: a swept-source optical coherence tomography study

Conditions: Crystalline Cataract; Lens; Anomaly

Summary: 230 participants at eye hospital of wenzhou medical university during june, 2019 and august, 2019 were enrolled in this study. 230 right eyes and 88 left eyes were included for the measurement. all the measurements were performed under non-mydriatic conditions in a dim examination room using the casia2 swept-source as-oct system.


Eligibility criteria:
inclusion criteria： * healthy volunteers and patients with age-related cataract exclusion criteria: * aphakia or pseudophakia * any other ocular diseases with the exception of senile cataract * any history of ocular surgery * fixation difficulties caused by any reasons

Keywords: crystalline lens tilt crystalline lens decentration swept-source optical coherence tomography
fame ii - fractional flow reserve (ffr) guided percutaneous coronary intervention (pci) plus optimal medical treatment (omt) verses omt

Conditions: Coronary Artery Disease

Summary: the overall purpose of the fame ii trial is to compare the clinical outcomes, safety and cost-effectiveness of ffr-guided pci plus optimal medical treatment (omt) versus omt alone in patients with stable coronary artery disease.

prospective, multi-center, multi-national, multi-continental, randomized clinical trial.

Eligibility criteria:
inclusion criteria: 1. patients with * stable angina or, * stabilized angina pectoris or, * atypical chest pain or no chest pain but with documented silent ischemia 2. at least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium 3. eligible for pci 4. signed written informed consent exclusion criteria: 1. patients in whom the preferred treatment is cabg 2. patients with left main coronary artery disease requiring revascularization 3. patients with a recent stemi or non-stemi 4. prior cabg 5. contra-indication to dual antiplatelet therapy 6. lvef \< 30% 7. severe lv hypertrophy 8. planned need for concomitant cardiac surgery 9. extremely tortuous or calcified coronary arteries precluding ffr measurements 10. a life expectancy of less than 2 years 11. age under 21

Keywords: stable angina angina pectoris pci fame fame ii ffr fractional flow reserve pressure wire
a trial of treatment for trauma-related nightmares in active duty military personnel

Conditions: Nightmares

Summary: the purpose of this study is to obtain preliminary data of the efficacy of exposure, relaxation, and rescripting therapy for nightmares among active duty military personnel.

this will be a pilot randomized controlled trial to compare the effects of exposure, relaxation, and rescripting therapy for military populations (errt-m) among active duty service members. participants will be randomized to 5 sessions of errt-m (n = 20 ) or to a 5-week waitlist control group (wl; n = 20). participants will complete all interviews and self-report measures 1 weeks following treatment or the wl condition and 1 month after completing treatment.

Eligibility criteria:
inclusion criteria: * active duty military stationed at fort hood as assessed by self-report. * able to speak and read english. * history of a traumatic event. * nightmare disorder * stable on psychotropic and/or hypnotic medications and/or interventions for sleep (e.g., continuous positive air pressure for sleep apnea) administered by other providers for at least one month assessed by self-report and review of medical record. * willingness to refrain from beginning new behavioral health or medication treatment for issues pertaining to sleep, ptsd, or nightmares during participation in the study. * indication that the sm plans to be in the area for the 5 months following the first assessment exclusion criteria: * current suicide or homicide risk meriting crisis intervention. * severe brain damage, assessed by the inability to comprehend baseline questionnaires. * pregnancy at baseline. * serious mental health diagnosis such as bipolar disorder or psychosis, assessed with the pre-treatment health interview and review of medical record. * currently taking propranolol. * currently engaged in evidence-based treatment for ptsd (i.e., prolonged exposure therapy or cognitive processing therapy) or insomnia (i.e., cognitive behavioral therapy for insomnia).
atomoxetine versus placebo in children with attention deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: atomoxetine versus placebo in children with attention-deficit/hyperactivity disorder (adhd)


Eligibility criteria:
inclusion criteria: * patients are diagnosed with adhd * patients must be able to swallow capsules * patients must be of normal intelligence exclusion criteria: * patients who weigh less than 15 kg or more than 75 kg * patients with organic brain disease (for example, dementia or traumatic brain injury residual)
mifepristone for treatment of uterine fibroids

Conditions: Uterine Fibroids

Summary: the objectives of this study are to estimate the efficacy and safety of the daily administration of mifepristone 5 mg versus 10 mg for three months for the treatment of uterine fibroids. the hypothesis of the study is that both mifepristone doses reduce the volume of the myoma in about 40% after 3 months of treatment.

women, in fertile age or in premenopausal status, presenting symptomatic uterine fibroids were randomly assigned to receive 5 mg or 10 of mifepristone. the diminishing of prevalence of symptoms attributable to uterine fibroids is the most important goal to achieve under both treatments. the possible side effects of mifepristone are slight and women's adherence to treatment is remarkable. also the reduction of the volumes of the uterus and fibroids contribute to enhance the wellbeing of subjects.

Eligibility criteria:
inclusion criteria: * symptomatic uterine leiomyomata * reproductive age or premenopausal * accepting the use of non hormonal contraception * conformity in keeping a monthly log of all episodes of vaginal bleeding during the treatment as well as all side effects of mifepristone * agreeing to have ultrasound examinations in every follow-up or evaluation visit * agreeing to two endometrial biopsies: one before starting treatment and another in the following 10 days after treatment termination. exclusion criteria: * pregnancy or desire to become pregnant * breastfeeding * hormonal contraception or any hormonal therapy received in the last three months * signs or symptoms of pelvic inflammatory disease * adnexal masses * abnormal or unexplained vaginal bleeding * suspected or diagnosed malignant neoplastic disease * signs or symptoms of mental illness * adrenal disease * sickle cell anemia * hepatic disease * renal disease * coagulopathy * any other severe or important disease * any contraindication to receiving antiprogestins

Keywords: uterine fibroids mifepristone antiprogestins
the impact of covid-19 pandemic on cancer care

Conditions: Cancer

Summary: the situation of covid-19 pandemic creates many challenges for cancer patients and caregivers. some modifications in cancer management have been evolved from cancer societies and organizations to support oncology professionals as much as possible to deliver optimal care to their cancer patients in such exceptional circumstances, and to protect patients from infection with covid-19 as much as possible.

in oncology practice during this pandemic, many cancer patients still feeling uncertainty about their cancer management and treatment outcome . the study is aiming to better understand the impact of the covid-19 pandemic on cancer care from patients' and survivors' perspective.

Eligibility criteria:
inclusion criteria: * cancer patients or survivors in egypt. exclusion criteria: * no exclusion criteria

Keywords: cancer care covid-19
the balance study: treatment of hyponatremia based on lixivaptan in nyha class iii/iv cardiac patient evaluation

Conditions: Hyponatremia

Summary: the purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.


Eligibility criteria:
inclusion criteria: * male and female patients 18 years of age or older with hyponatremia and hospitalized for congestive heart failure.

Keywords: hyponatremia serum sodium fluid overload heart failure acute heart failure vasopressin antagonist
safety and efficacy of three formulations of agn-210669 ophthalmic solution compared with bimatoprost ophthalmic solution

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this study will evaluate the safety, efficacy and dose-response of agn-210669. this study will also compare agn-210669 with bimatoprost ophthalmic solution (lumigan®).


Eligibility criteria:
inclusion criteria: * ocular hypertension or primary open-angle glaucoma in each eye * patient requires iop lowering medication in each eye exclusion criteria: * ocular hyperemia or other ocular surface findings in either eye * active ocular disease * current or anticipated use of any topical ocular medication (including artificial tears) during the study * intraocular surgery within past six months or unilateral cataract surgery. * functionally significant visual field loss * anticipated wearing of contact lenses during study * use of other medications that affect iop such as glaucoma treating medications, within 2 months of screening visit
up-down oxytocin infusion

Conditions: Uterine Atony

Summary: this study is designed to determine the minimum effective dose (ed90) of infusions of oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for additional uterotonics, in low risk parturients presenting for an elective cd. the primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.


Eligibility criteria:
inclusion criteria: 1. non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery) 2. american society of anesthesia physical status class i \& ii (asa i - healthy, asa ii - mild and controlled systemic disease, eg. controlled essential hypertension) 3. age ≥ 18 years 4. term gestational age (≥ 37 weeks) 5. english-speaking exclusion criteria: 1. morbid obesity (body mass index ≥ 45 kg/m2) (morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study and the blood pressure cuff occasionally needs to be replaced by an intraarterial catheter due to limitations in size) 2. laboring women 3. urgent or emergency cesarean delivery 4. severe hypertensive disease of pregnancy defined as systolic blood pressure (sbp) \> 160mmhg, diastolic blood pressure (dbp) \> 110mmhg and/or requiring antihypertensive treatment or associated with significant proteinuria 5. severe maternal cardiac disease 6. subjects predisposed to uterine atony and postpartum hemorrhage (i.e. placenta previa, multiple gestation, macrosomia, polyhydramnios, uterine abnormalities, or bleeding diathesis, \> 2 previous cd) 7. fetal anomalies /intrauterine fetal demise 8. failed spinal anesthesia 9. patient enrollment in another study involving a study medication within 30 days of cd 10. any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
indirect magnetic resonance lymphangiography of the head and neck region using conventional gadolinium-based contrast

Conditions: Head and Neck Cancer; Head and Neck Cancers

Summary: to determine the ability of magnetic resonance lymphangiography using conventional gadolinium injected directly into the tumor site and pet scan in detecting microscopic nodal metastasis in patients with newly diagnosed h\&n cancers


Eligibility criteria:
inclusion criteria:patients with newly diagnosed squamous cell carcinomas of the h\&n with primary tumor sites that are accessible to direct contrast injections
safety and effectiveness of trizivir (abacavir/lamivudine/zidovudine) with efavirenz in hiv-infected patients who have never taken anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to determine the effect of treatment with trizivir (tzv) plus efavirenz (efv) or tzv alone on viral load (level of hiv in the blood).

patients receive tzv plus efv in the 48-week induction phase. eligible patients, defined as those with plasma hiv-1 rna under 50 copies/ml, participate in the 48-week maintenance phase. patients are randomized equally to receive either tzv plus efv or tzv alone. an immunology substudy will be conducted, including approximately the first 100 patients enrolled who agree to participate.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are at least 13 years old. * are hiv-positive. * have a viral load of at least 5,000 copies/ml. * agree to use adequate and reliable methods of birth control. note: hormonal birth control is not considered adequate. * provide written consent of a parent or guardian, if under 18 years of age. exclusion criteria patients will not be eligible for this study if they: * have taken nonnucleoside reverse transcriptase inhibitors. * have taken other anti-hiv drugs for 2 weeks or more. * have an opportunistic (aids-related) infection. * are pregnant or breast-feeding. * have had hepatitis within the past 6 months. * are allergic to the study drugs or their ingredients. * have a mental, physical, or substance abuse disorder. * have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease. * have a gastrointestinal disorder that affects drug absorption or makes it difficult to take medication by mouth. * have received within 4 weeks before study entry, or may require during the study period, radiation therapy, chemotherapy, or drugs that affect the immune system (such as steroid drugs, interleukins, vaccines, or interferons). * have received an hiv vaccine within 3 months before study entry, or are scheduled to receive one during the study period. * require foscarnet or other drugs that are shown to be effective against hiv. * are taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives. * are taking experimental drugs. * are unlikely to complete the study or take the drugs.

Keywords: hiv-1 drug therapy, combination zidovudine lamivudine drug combinations rna, viral reverse transcriptase inhibitors anti-hiv agents viral load abacavir efavirenz
(sgb) in men treated for prostate cancer improve hot flashes

Conditions: Prostate Cancer; Hot Flashes

Summary: androgen deprivation therapy (adt) is a critical component of advanced prostate cancer treatment but causes numerous adverse effects including decreased bone mass, decreased muscle mass, gynecomastia, erectile dysfunction, loss of sexual desire, depression, disordered sleep, urinary symptoms, and hot flashes (hf). hf are unpleasant paroxysmal episodes of flushing, sweating with vasodilation of the face, neck, and chest. these episodes can last for seconds to minutes and are often associated with night sweats, anxiety, and insomnia and have negative effects on quality of life. stellate ganglion blockade (sgb) with local anesthetic may be an effective treatment of hf in men on adt, but has not been studied in any published clinical trials. the stellate ganglion is a neural structure in the anterior cervical spine region and is part of the sympathetic nervous system. it has been injected safely in the practice of pain management for more than 50 years in cases of post herpetic neuralgia (shingles), complex regional pain syndrome (crps) and other painful neuropathies as well as some types of cardiac dysrhythmias. given the frequency and severity and interference of hf in men on adt for prostate cancer, in addition to the negative effects hf impose on this patient population and a paucity of effective treatments, finding alternative treatments for hf in this population is needed.


Eligibility criteria:
inclusion criteria: 1. men with prostate cancer (with or without metastatic disease) on adt for at least 2 months 2. age less than 65 years 3. body mass index (bmi) less than 32 4. willingness to undergo image guided intervention 5. greater than 28 hot flashes per week. exclusion criteria: 1. conditions that preclude sgb or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; metastatic disease in or near the cervical spine; goiter;cardiac/pulmonary compromise; sleep apnea; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye) 2. current treatment of prostate cancer with radium or chemotherapy 3. use of treatments in the past two months that can affect hf (e.g., testosterone or androgen supplementation) note: ssris, serotonin norepinephrine uptake inhibitors, and membrane stabilizers will be allowed but must be on stable unchanged dose for at least 8 weeks) 4. inability to write, speak, or read in english

Keywords: stelate ganglion block
optimal timing for spontaneous breathing trials

Conditions: Respiration, Artificial; Weaning

Summary: this study aims to explore how the timing of spontaneous breathing trials (sbts) affects recovery in adult patients who are on mechanical ventilation in the icu. sbts are tests used to determine if a patient is ready to breathe on their own without the help of a ventilator. the study will compare two different timing strategies for these trials: one group of patients will have the test early in the morning, while the other group will have it later in the morning. by observing the outcomes, such as how long patients need to stay on the ventilator, the study hopes to find the best time to perform these trials to help patients recover more quickly and safely.

this study seeks to understand how the timing of spontaneous breathing trials (sbts) impacts the recovery of adult patients who are on mechanical ventilation in the intensive care unit (icu). mechanical ventilation is a life-support technique used for patients who are unable to breathe on their own. the spontaneous breathing trial is a key step in assessing whether a patient is ready to breathe independently and can safely have the ventilator removed. currently, there is no universal standard for the best time of day to conduct these trials. some hospitals perform sbts early in the morning, while others wait until later in the morning when more staff are available. this study will compare two groups of patients: one group will have their sbts early in the morning, and the other group will have them later. the primary goal is to determine whether the timing of these trials affects how long patients need mechanical ventilation, how quickly they can be safely extubated (removal of the breathing tube), and overall recovery outcomes, such as icu stay and hospital discharge.

Eligibility criteria:
inclusion criteria: * adults aged 21 years or older. * patients who have been on mechanical ventilation for more than 48 hours. * patients who have completed at least one sbt. exclusion criteria: * patients intubated at other hospitals. * patients intubated for surgical or interventional procedures. * patients receiving venovenous extracorporeal membrane oxygenation (vv-ecmo). * patients with a tracheostomy.

Keywords: spontaneous breathing trial weaning mechanical ventilation duration